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Abstract: Changes in the number of chromosomes, but also variations in the copy number of chromosomal regions have 
been described in various pathological conditions, such as cancer and aneuploidy, but also in normal physiological condi-
tion. Our classical view of DNA replication and mitotic preservation of the chromosomal integrity is now challenged as 
new technologies allow us to observe such mosaic somatic changes in copy number affecting regions of chromosomes 
with various sizes. In order to go further in the understanding of copy number influence in normal condition we could take 
advantage of the novel strategy called Targeted Asymmetric Sister Chromatin Event of Recombination (TASCER) to in-
duce recombination during the G2 phase so that we can generate deletions and duplications of regions of interest prior to 
mitosis. Using this approach in the mouse we could address the effects of copy number variation and segmental ane-
uploidy in daughter cells and allow us to explore somatic mosaics for large region of interest in the mouse.  
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INTRODUCTION 
  Our knowledge about human genetic variation has con-
siderably evolved in the past few years with the development 
of genome-wide technologies unrevealing structural varia-
tions such as oligonucleotide microarray technologies and 
the next-generation sequencing with “paired-end” methods 
[1] that enable to screen the genome at a submicroscopic 
level. The identification of frequent copy number variants 
(CNVs) between individuals, including deletions and dupli-
cations of DNA sequences has definitely changed our view 
of genome integrity. Thousands of different CNVs have been 
identified (http://projects.tcag.ca/variation) overlapping a 
large number of genes [2, 3] and accounting for about 13% 
of the human genome. Estimates suggest that CNVs account 
for up to 24 Mb [3, 4] of the genetic difference between in-
dividuals, exceeding single nucleotide polymorphism (SNP) 
(2.5 Mb) [5].  
  In addition of being a major source of genetic diversity in 
the human population, CNVs are also responsible for various 
pathological conditions such as cancer, aneuploidies and 
contiguous gene syndromes (CGS). The first CNVs that 
were recognized were due to large chromosomal rearrange-
ments that were visible under light microscope, causing well 
known genomic disorders such as Down (trisomy 21), 
Turner (monosomy X), Fragile X (Xq27.3) or Cri du Chat 
(del 5p-) syndromes [6]. These genomic disorders are often  
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sporadic as they are de novo mutations leading to severe 
developmental deficits not compatible with the individual 
having offsprings. However, some CNVs can be inherited in 
a Mendelian way: Charcot-Marie-Tooth disease type 1A is a 
dominant neuropathy associated to a duplication of the gene 
for peripheral myelin protein 22 (PMP22) [7], whereas a 
deletion of the b-globin gene cluster is responsible for the 
recessive anemia-thalassemia [8]. The number of recognized 
genomic disorder has been drastically increasing since the 
1980s by the constant discovery of submicroscopic (<5 Mb) 
genomic deletions and duplications associated with 
pathological phenotypes [9, 10]. Microdeletion 15q11.2q12 
was associated with Prader-Willi syndrome in 1981 [11], a 
17p13.3 deletion was found in Miller-Dieker lissencephaly 
syndrome [12], a 1.5 to 3.0-Mb hemizygous deletion of 
chromosome 22q11.2 causing haploinsufficiency of the 
TBX1 gene was discovered in DiGeorge syndrome [13], 
whereas the first recurrent microduplication was identified in 
1991 in patients with Charcot-Marie-Tooth disease type 1A 
(CMT1A) [7]. In particular, the discovery of new CNVs has 
increased the diagnostic of mental retardation symptoms that 
affect 2-3% of the population as define new recognized syn-
dromes by 15-20%. Moreover, CNVs are increasingly asso-
ciated with complex traits such as autism [14, 15], schizo-
phrenia [16] or epilepsy [17, 18] and susceptibility to infec-
tious diseases such as HIV [19], Crohn disease [20, 21], pso-
riasis [22] or malaria [23].  
  A major mechanism by which rearrangements can cause 
a phenotype is by altering the copy number of a gene (or 
genes) sensitive to a dosage effect and influencing its ex-
pression [24]. But deletions and duplications can also cause Cre-Induced Segmental Copy Number Variation  Current Genomics, 2010, Vol. 11, No. 6    471 
gene expression perturbation through positional effect [25]. 
This position effect can be either the result of the physical 
dissociation between the transcription unit and its regulatory 
sequences that can sometimes lie as far as 1 Mb away from it 
[26, 27], or the result of the alteration of local or global regu-
lation of chromatin structure [28-31]. These effects have 
been documented by some human disease states. For exam-
ple, Aniridia (absence of the iris) due to haloinsufficiency of 
PAX6 at 11q13 has been shown to result from a chromoso-
mal rearrangement that disrupts the region downstream of 
PAX6 transcription unit [32-35]. Human diseases resulting 
from aberrant gene expression through altered chromatin 
structures include FSHD (facioscapulohumeral dystrophy) 
(MIM 158900), a neuromuscular disorder affecting the facial 
and shoulder girdle muscles and one case of -Thalassemia 
(MIM 141800) in which the HBA2 gene has been silenced by 
methylation of its promoter region by an antisense RNA de-
rived from the truncated neighboring LUC7L gene on the 
opposite strand [31]. Genomic rearrangements of the genome 
can also trigger phenotypes by unmasking of recessive muta-
tions or functional polymorphism of the remaining allele in 
the case of deletions. Hence, it was shown that, in Sotos syn-
drome that is due to del 5q35, the severity of the disease de-
pends on the polymorphism of the remaining copy of the 
coagulation factor 12 gene [36].  
  CNVs often arise from meiotic recombination between 
highly similar (<97% sequence identity) duplicated se-
quences (termed low-copy repeats or LCRs) located less than 
10 Mb apart. LCRs represent up to 5% of the haploid human 
genome [37] and can cause genomic instability as they can 
be at the origin of misalignment of chromosomes or chro-
matids and cause nonallelic homologous recombination 
(NAHR), resulting in unequal crossing-over [38]. But other 
mechanisms have been also proposed to be responsible for 
CNVs formation: nonhomologous end joining (NHEJ) is a 
mechanism that repairs DNA double strand breaks and, 
when defective, can lead to translocations and telomere fu-
sion, hallmark of tumor cells [39]. Fork stalling and template 
switching (FoSTeS), a DNA replication error mechanism, 
has recently been shown to play an important role in the ori-
gin of nonrecurrent rearrangements with a complex structure 
leading to genomic disorders of various size [40-42]. Several 
studies have predicted that NHEJ or FoSTeS are at the origin 
of some CNVs observed in some cases of Duchenne muscu-
lar dystrophy, Smith-Magenis syndrome and Pelizaeus-
Merzbacher disease [43, 44]. These mechanisms have the 
particularity of leading to CNV mosaicism. Occurrence of 
somatic mosaicism has been reported for chromosomal aber-
rations connected with diseases and leading to a milder phe-
notype of the disease [45, 46], arising somatically in cancers 
[47-49], or in the case the rearrangements of the immuno-
globulin and T-cell-receptor genes [50]. In healthy individu-
als, more and more data have recently accumulated showing 
inter- and intra- tissues mosaicism for entire chromosome 
aneuploidies in germ cells, placenta, brain, skin, liver and 
blood [51, 52], although their occurrence remains unclear, 
due to the techniques that use pooling of large number of 
cells to study CNVs. Recent studies have started to point out 
at the importance of CNVs somatic mosaicism: extensive 
chromosomal instability and de novo recurrent CNVs have 
been reported in human cleavage-stage [53] and in mouse 
embryonic stem cell [54] respectively and somatic CNV mo-
saicism has been reported in different human tissues and 
organs [55] with studies on monozygotic twins revealing 
putative de novo somatic CNV events [56]. In a paper pub-
lished this year, the group of Anja Weise at the Institute of 
Human Genetics in Magdeburg (Germany) provided the first 
evidence of somatic mosaicism for CNV between different 
cell types of one individual [57]. They used an approach that 
was defined to determine chromosomal parental origin in 
single cells based on fluorescent in situ hybridization (‘pa-
rental-origin-determination fluorescence in situ hybridiza-
tion’ or pod-FISH) [58] to visualize CNVs on homologous 
chromosomes metaphase spreads from 10 healthy individu-
als and found CNV variation between different cell types but 
not within one cell type. They hence propose that there is 
early embryonic chromosome instability which results in 
stable mosaic pattern in human tissues. 
  While CNV is now recognized as a major source of ge-
netic variability between individuals, their biological conse-
quences are largely under investigated. Analysis of their 
pathological role and molecular mechanism are hard to in-
vestigate in human and require an animal model, genetically, 
morphologically and physiologically closer. The mouse con-
stitutes a model organism of choice with an anatomy, physi-
ology and genetics highly similar to humans. 80% of mouse 
genes have an orthologous counterpart in the human genome 
[59] and 99% have a sequence match. Homologous genes are 
found in the same order and relative orientation in large 
blocks of conserved syntenic regions. In addition, the ability 
to manipulate the mouse genome has made the mouse the 
primary mammalian genetic model organism. CNV can be 
artificially created using various chromosome engineering 
techniques that enable to precisely manipulate large genomic 
regions. Especially, the technology based on the Cre-loxP 
system is used to generate new chromosomes carrying dele-
tions, duplications, inversions and translocations in targeted 
regions of interest and to study contiguous gene syndromes 
as well as normal developmental processes associated with 
CNV.  
I. GERM LINE GENETIC ENGINEERING USING 
EMBRYONIC STEM (ES) CELLS 
  Modelling chromosomal rearrangements such as dele-
tions, duplications, inversions or translocations in the mouse 
genome has been made possible by combining gene targeting 
in embryonic stem (ES) cells [60-63] with site-specific re-
combinase (SSR) systems such as the Cre-loxP [64]. Gene 
targeting enables to introduce small DNA sequences known 
as loxP sites to predefined loci by homologous recombina-
tion. Subsequent expression of the bacteriophage Cre recom-
binase that catalyses recombination between loxP sites [65-
68] and can act in the mammalian genome without any co-
factor, allow to generate large chromosomal rearrangements 
either in ES cells and then transmitted to the mouse by in-
jecting the transformed ES cells to blastocysts, or directly in 
the mouse. The size of the loxP, small enough to be intro-
duced very easily by genetic engineering and large enough to 
avoid problems associated with cryptic occurrence in eu-
karyotic genomes, has made the Cre-loxP system a very sim-
ple and powerful tool for mouse genomic engineering.  472    Current Genomics, 2010, Vol. 11, No. 6  Hérault et al. 
 Cre-loxP recombination in ES cells can be easily gener-
ated for deletions of small regions (<100 kb) with insertion 
of two loxP sites in a direct orientation and cis configuration 
[69, 70]. However, to obtain larger deletions or duplications 
with loxP sites on different chromosomes the frequency of 
the recombination is too low and requires to be selected 
through the restoration of a positive selection marker [71-75] 
or by the deletion of a negative selection marker [76-79]. To 
this end, targeting vectors were designed, containing the 5’or 
3’ part of the HPRT minigene with loxP located downstream 
and upstream respectively [71]. Use of this technique has 
been largely facilitated by the creation and the allocation of 
specific targeting vectors [80] that are now mapped on the 
mouse genome (Mutagenic Insertion and Chromosome En-
gineering Resource [MICER], http://www.sanger.ac.uk/Post-
Genomics/mousegenomics/) [81], avoiding the fastidious 
and time-consuming task of constructing the targeting vec-
tors. In addition, retroviral vectors can be used to target the 
second loxP site providing new loxP sites nested insertions 
extending from a few kb to several Mb around defined loci 
[82].  
 Although  Cre-loxP recombination is a very powerful and 
convenient technique, it has to be carefully planned as its 
efficiency depends on many factors. Obtaining deletion, du-
plication or inversion depends on the position (cis or trans) 
of the loxP site, the relative orientation of the two loxP sites 
and on the cell cycle stage during which the Cre-mediated 
recombination occurs [83, 84]. Cre-mediated recombination 
efficiency depends on the recombinase activity [85], the re-
gion targeted that could induced ES cell lethality after dele-
tion [86], the genetic distance between the loxP sites in a cis 
configuration (10%-0.1%) and the configuration of the loxP 
sites [71, 84, 87]. The size of the deletions is limited by hap-
loinsufficiency of genes within the deleted interval that can 
trigger ES cell lethality and can be circumvented by making 
balancer deletion/duplication using trans recombination.  
  The possibility of manipulating large chromosomal re-
gions has provided the scientific community with the oppor-
tunity to develop mouse models of CGS. Models developed 
for for del22q11.2 (DiGeorge syndrome) [88, 89] enabled to 
identify TBX1 as a candidate gene for the pathology [90]. 
Modeling Down syndrome (DS), the only viable autosomal 
aneuploidy in human, requires multiple chromosomal rear-
rangements as the around 300 human chromosome 21 or-
tologs are found in three syntenic regions on mouse chromo-
somes (Mmu) 10, 17 and 16. The phenotypic analysis of the 
Ts65Dn and Ts1Cje models obtained in a random manner 
and trisomic for part of the MMU16 [91-93], the Ts1Rhr 
trisomic for a ~5 Mb Down syndrome critical region (DCR) 
[72, 94] and the Ts1Yah model trisomic for the syntenic re-
gion on Mmu17 [95], both generated by chromosomal engi-
neering, start to reveal the complexity of the genetic interac-
tions at the origin of the disease. Mouse models have also 
been created for the Smith-Magenis [96-99] and Prader Willi 
[100] CGS, and to study large genes or cluster of genes such 
as the HoxD genes cluster [70], the Duchenne muscular dys-
trophy gene [75], the amyloid precursor protein gene [76] or 
the  Nf1 gene [77]. Cre/loxP chromosome engineering in 
mouse ES cells was also developed to generate transloca-
tions or deletions similar to those found in cancer [86, 101-
105]. Finally, in 2009, a mouse model was created for the 
first time to model a polygenic disease [106]. Autism, a 
common heterogeneous psychiatric disorder is a develop-
mental brain disease characterized by deficit in social inter-
action and communication, and stereotyped repetitive behav-
iour. Autism has been shown to have a strong genetic basis 
with chromosomal anomalies accounting for 10 to 20% of 
the cases [107]. Among these anomalies, chromosome 
15q11-13 duplication is the only recurrent cytogenetic aber-
ration that could be associated with autism. Nakatani and 
collaborators (2009) generated a 6.3 Mb duplication of the 
conserved linkage group on Mmu7 and showed that the 
mouse model generated recapitulated aspects of human 
autism such as social abnormalities and increased anxiety 
and fear, providing a new tool to decipher the physiological 
and molecular mechanism underlying this pathology.  
II.  IN VIVO GERMLINE CRE-LOXP RECOMBINA-
TION 
  Creating chromosomal rearrangements in the whole or-
ganism offers an alternative to the in vitro protocol that is 
very labor-intensive and requires many rounds of ES cells 
genomic manipulations (Fig. 1). It requires that the loxP sites 
recombination occurs either in germ line cells during meiosis 
or ubiquitously in all of the tissues or in early embryogene-
sis. The rearrangements can then be transmitted to the prog-
eny. This can be achieved by using Cre transgenic lines such 
as Sycp1-Cre [108], Zp3-Cre  [109, 110], Protamine-Cre 
[111],  CMV-Cre  [112], R26Cre [113] or Hprt-Cre  [114]. 
Most of the large in vivo rearrangements are deletions that 
are obtained from two loxP sites in the same relative orienta-
tion inserted in cis in ES cells [70, 115-117]. The frequency 
of recombination in cis decreases with the increasing dis-
tance between the loxP sites (0.3%-1%), but still remains 
high enough to be workable up to distances reaching 28 Mb 
[118]. For loxP sites that are originating from different 
mouse founder lines and hence are not in cis, deletion can 
still be obtained by mating the two founder lines and select-
ing for recombination after classical crossing-over, a tech-
nique called STRING for Sequential Targeted Recombina-
tion INduced Genomic rearrangement [118]. Similarly, in-
versions have been obtained in vivo with two loxP sites lo-
cated in the same chromosome but with a reverse orientation 
[115, 119]. The different ubiquitously expressed Cre trans-
genic lines are not all similarly efficient in making the re-
combination and can lead to mosaic individuals in the first 
generation [73, 120, 121]. An alternative to the ubiquitous 
Cre transgenic lines is the Zp3-Cre in which cre expression 
is controlled by regulatory sequences from the mouse zona 
pellucida gene, expressing exclusively in the growing oocyte 
prior to the completion of the first meiotic division. But this 
transgenic Cre line was also shown to produce some mo-
saicism in a mouse model for DiGeorge del22q1 syndrome 
[122]. 
  Creating chromosomal duplications requires that the two 
loxP sites are on homologous chromosomes (trans) and is 
only possible when the two homologous chromosomes be-
comes physically close together. A strategy called TAMERE 
for TArgeting MEiotic Recombination was designed by 
Herault et al. (1998) [108] that makes use of a Cre under the 
control of the Synaptonemal Complex 1 promoter that is 
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when chromatid pairs are closely aligned [123], enabling 
trans recombination [115, 124, 125]. However, for larger 
genomic rearrangements, while in vivo recombination is still 
effective for cis configurations up to 28 Mb [118], no rear-
rangement was obtained for a distance of 3.9 Mb [126] and 
hence seems to be limited to short-distance recombination. 
The TAMERE strategy has been used extensively to rear-
range and study the HoxD complex region [108, 119, 127, 
128] and has also been used to address the functional rela-
tionship between PrPc and Dpl, two genes involved in Prion 
disease, by making a double deletion of these two genes that 
are separated by 16 kb [125].  
 Beside  the  Cre-loxP system described here, the Flp-FRT 
system is another tyrosine site-specific recombinase (SSR) 
system that has been used as tool for DNA and genome en-
gineering. However, FLP recombinase was found to be less 
efficient than Cre, partly due to an unsuitable optimum tem-
perature for mammalian cells [129]. Recently, a new Cre-
like recombinase, called Dre, was identified from P1-related 
phage D6 by Sauer and McDermott (2004) [130]. Dre re-
combinase has DNA specificity for a 32 bp DNA site (rox) 
distinct from the loxP and shows no cross-recombination 
with the Cre-loxP system. Like the Cre, it catalyzes both 
integrative and excisive recombination and requires no co-
factor. The Dre-rox system was validated in the mouse by 
Anastassiadis and collaborators (2009) [131] who tested the 
efficiency of Dre-rox recombination in vivo by developing 
ubiquitous mouse lines based on the CAGGs promoter [132] 



























Fig. (1). Schematic representation of the different in vivo strategies developed to model CNV in the mouse. (A) In the TAMERE strat-
egy, loxP sites are inserted in a trans configuration and expression of the Cre recombinase during meiosis enables to generate cells containing 
a duplication with the reciprocal deletion. (B) The STRING approach takes advantage of the classical crossing-over to bring the two loxP 
sites into a cis configuration to generate a deletion. (C) Inter-chromosomal recombinations are obtained by introducing loxP sites at the site 
of the desired rearrangement and expressing the Cre recombinase. (D) The MADM strategy base on Cre-mediated inter-chromosomal re-
combination and G2-X segregation during mitosis, offers the possibility to introduce mosaicism in vivo. (E) The TASCER strategy takes 
advantages of the G2 stage of the S phase to recombine loxP sites in cis, leading to the deletion and the duplication of the sequence sur-
rounded with the loxP.  474    Current Genomics, 2010, Vol. 11, No. 6  Hérault et al. 
toolkit for mouse genome engineering. Finally, recent appli-
cations for large serine SRRs such as phiC31 and phiBT1 
[133] in eukaryotic genome engineering have emerged as 
new additional tools. 
  Association of the Cre-loxP system with transposon-
based approaches should considerably speed up the genera-
tion of large-scale rearrangements in vivo. Transposons are 
mobile genetic elements that function as a bipartite system 
with a transposase to move around to different positions 
within the genome, potentially perturbating gene function. 
They have been extensively used for random mutagenesis 
and have been shown to be efficient both in vitro in ES cells 
and in vivo in the germline or somatically [134-141]. The 
most widely studied transposon/transposase system for 
mammalian mutagenesis is the Sleeping Beauty transposon 
of the Tc1-like mariner family [142]. Transposons have the 
advantage that they are active in vivo and only require breed-
ing of transgenic mice, their insertion sites can be defined 
thanks to the transposon serving as a tag. More recently, an 
alternative transposon called Piggybac, derived from the 
cabbage looper moth (trichoplusia ni) has been developed, 
that can carry larger payloads between its transposon repeats 
[138]. PiggyBac transposons offer the possibility to easily 
distribute loxP sites throughout the mouse genome and, as-
sociated with the Cre-loxP technology, permit to generate 
rapidly and easily genome-wide chromosome rearrange-
ments [121].  
III. SOMATIC GENETIC ENGINEERING 
  Mosaicism in copy number variation has been observed 
in human [143]. It is a direct consequence of the missegrega-
tion of a chromosome during mitosis: while the two copies 
of one homologous chromosome migrate in one daughter 
cell that will be trisomic, the second will have only one copy 
being now monosomic. 
  The percentage of aneuploid mosaicism depends on the 
developmental stage, the lineage of the cell that is affected 
and its viability, and the type of chromosomal rearrangement 
produced. If the rearrangement occurs early during embryo-
genesis, the mosaicism can be generalized to all cell lineages 
and can result in major phenotypic changes that are often 
lethal. For example, in Turner syndrome more than 98% of 
conceptuses that are 45, X do not survive to term and only 
mosaic are thought to be compatible with life [144].  
  Mosaic aneuploidy can be registered in all somatic cell 
populations contributing to normal inter individual variabil-
ity, with a frequency of 1.25–1.45% per chromosome and a 
percentage of aneuploid cells above 30% reported in blood 
cells [145] and brain [146-148]. Reasons for the presence of 
such aneuploid cells and its consequence remain for the 
moment speculative.  
  Consequences of somatic aneuploid mosaicism can be 
analysed in the mouse by generating segmental aneuploid 
mosaicism in mouse tissues using the Cre-loxP system dur-
ing the G2 phase of mitosis. Two different strategies were 
developed using this system. Zong et al. (2005) [149] devel-
oped a technique utilizing Cre-mediated inter-chromosomal 
recombination prior to cell division (mitotic recombination) 
and took advantage of the G2-X segregation during mitosis 
to induce recombination events between homologous chro-
mosomes in somatic cells and to mark the resulting daughter 
cells with different genotypes. They called this technique 
Mosaic Analysis with Double Markers (MADM). In addition 
to create and study sporadic loss of heterozygosity, this tech-
nique can also be used with a pre-introduced deletion or du-
plication on one chromosome to create CNV mosaics com-
posed of wild-type daughter cells bearing the normal allele 
or mutant cells containing the allele with the deletion or the 
duplication. Another strategy takes advantages of the prop-
erty of the Cre recombinase to react on G2 phase of mitosis 
to directly generate different types of cells with either the 
duplication or the deletion of one chromosomal region tar-
geted with the loxP sites [150]. The TASCER (Targeted 
Asymmetric Sister Chromatid Recombination) takes advan-
tage of the presence of loxP sites on sister chromatids after 
replication of DNA in G2 phase during mitosis in order to 
generate in vivo cells harbouring microdeletions and micro-
duplications. LoxP sites were inserted on the same chromo-
some in a cis configuration separated by up to 2.2 Mb. Upon 
mating Cis/+ mice with a general Cre deleter line, mosaic 
animals were obtained with cells containing either the dele-
tion or the duplication. Indeed, if loxP recombination occurs 
after DNA replication, in addition to the expected deletion, 
the corresponding duplication was also obtained correspond-
ing to the intermediate reaction product containing three loxP 
sites. The duplication with presence of three loxP sites repre-
sents the intermediate product between the double cis con-
figuration with four loxP sites of the G2 stage cells and the 
deletion end product. This is the first report of an in vivo 
generated duplication coming from a cis configuration, pre-
sumably because, in most reports, loxP sites were not as dis-
tant, resulting in a better efficiency avoiding the presence of 
the intermediate genomic duplication configuration. Hence, 
the increased distance tends to decrease the Cre-mediated 
recombination frequency [87] somehow preserving the 
chromosome with a large duplication. Using TASCER on 
two chromosomal regions homologous to the telomeric part 
of human chromosome 21, cells with partial monosomy and 
trisomy were efficiently recovered at a relatively constant 
level in numerous different tissues. The TASCER mecha-
nism necessitates that the Cre is particularly active during 
the G2 phase during cell proliferation. This phenomenon has 
been described in vitro in embryonic stem cells [84, 151] but 
with much less efficiency than in vivo. The reason for this 
discrepancy might be that expression of the Cre is more sta-
ble in vivo and that the in vivo environment is more favour-
able to the viability of the aneuploid cells. Change in the 
chromatin structure, with complexes such as the cohexin one 
inducing physical connection of sister chromatids, can also 
facilitate the mitotic recombination [152, 153]. 
  Efficiency of the TASCER is also depending of the type 
of Cre transgenic line used, as these do not express the Cre 
recombinase with the same efficacy. Hence, Duchon et al. 
(2008) [150] were able to induce up to 2.2 Mb deletions and 
duplications with a set of three different Cre lines, but could 
not obtain a larger modification of 9.2 Mb that might require 
a Cre line with a stronger promoter such as the CAG pro-
moter inserted in the Hprt locus of the Hprt1
tm1(Cre)Mnn mouse 
line, which has been used successfully in a recent study 
[114]. The fact that cells bearing the duplication was found Cre-Induced Segmental Copy Number Variation  Current Genomics, 2010, Vol. 11, No. 6    475 
in many different organs despite the less stable presence of 
three loxP sites [154] indicates that the trisomic state might 
be beneficial in some tissues and point out at the necessity to 
be very careful when using the Cre-loxP system in vivo to 
generate deletions.  
  Whereas chromosomal mosaicism has been observed in 
pathological conditions, such as Turner syndrome [155] or in 
cancer [156], the TASCER publication did not report any 
dramatic changes in the survival of trisomic and monosomic 
cells produced. In some tissues such as the muscle, this can 
be explained by compensatory effects due to their organiza-
tion in a plurinuclear syncitia. However, in other non 
syncitial tissues, other mechanisms such as non-cell autono-
mous effect should be proposed to explain this phenomenon.  
  Although mosaic aneuploidy and CNVs have been re-
ported in nonpathological conditions in different cell popula-
tions such as neurons [51, 52, 146-148, 157-159], their role 
and biological consequence to the organ structure and func-
tion in health and disease remains under explored. In the 
brain, mosaic DNA rearrangements have been suggested to 
contribute to the mechanism for neuronal cell diversification 
[160]. However, these are only suppositions and there is to 
date little evidence supporting a functional consequence for 
mosaic CNV in nonpathological conditions. To answer those 
questions, future studies need to examine the effect of so-
matic CNV on cell physiology. TASCER that results into 
substantial segmental aneuploid mosaicism, offers the possi-
bility to explore consequences of such a phenomenon in a 
model organism. It further can be used to to induce partial 
aneuploid conditions such as those detected in cancer cells 
and to study further the consequence of loss or gain of copy 
number for chromosomal regions during tumorigenesis 
[156], avoiding the fastidious need of gene-by-gene inactiva-
tion or ES-cell MICER recombination system to study such 
phenomenon. TASCER hence offers new perspective for the 
generation and analysis of CNV variation in health and dis-
ease.  
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